Trypanosoma cruzi LYT1 mRNA-binding proteins. Supplementary materials.

The present data show an overview of the proteins expressed in the epimastigote and trypomastigote stage of T. cruzi associated with LYT1 mRNA UTRs, a virulence factor reported in this parasite species. The set of proteins associated with LYT1 UTRs in the infective stage of T. cruzi Trypomastigote or in one of the replicative stages of this parasite, the epimastigote, provide relevant information on the proteome of the etiological agent of Chagas disease. This list of proteins will allow those interested in this topic to functionally characterize proteins of interest and to apply the construction of simulations or in silico models using bioinformatics tools.A set of proteins associated with each UTR of LYT1 mRNA becomes a starting point to elucidate the direct or indirect role of each protein factor in the regulation of LYT1 protein isoform expression. New proteins were identified in T. cruzi recorded here by our research group, expanding the proteome databases of this medically important parasite.THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV

No evidence for the effectiveness of systemic corticosteroids in acute pharyngitis, community-acquired pneumonia and acute otitis media

Corticosteroids have been used to treat infectious diseases for more than 50\ua0years but, although it has been shown that they are highly effective in improving the clinical course of some diseases, their effects have not been clearly defined in others. Nevertheless, they are still used by a considerable number of physicians. This review analyses the role of systemic corticosteroids in the treatment of acute pharyngitis (AP), community-acquired pneumonia (CAP) and acute otitis media (AOM). A number of trials involving patients with AP have been carried out, but most are marred by methodological flaws that do not allow any firm conclusions to be drawn. The number of trials involving CAP patients is even higher, and the data suggest that corticosteroids may reduce the risk of death only in patients with severe disease. There are very few data concerning AOM, and there is currently no reason for prescribing corticosteroids to treat it. Overall, the data showed that there is, currently, no indication for the universal use of systemic corticosteroids in any of the reviewed diseases and, further, high-quality studies of all of these respiratory tract infections are needed in order to identify the patients for whom the prescription of corticosteroids is rationally acceptabl